可溶性鸟苷酸环化酶激活剂runcaciguat显著改善CKD患者白蛋白尿
这项2a期随机安慰剂对照试验纳入243例CKD患者,评估runcaciguat(30-120mg每日一次,滴定8周)对白蛋白尿的疗效。结果显示,在符合方案集中,无论是否联用SGLT2i,runcaciguat均显著降低UACR(不联用SGLT2i组较安慰剂降低45.2%,P<0.001;联用SGLT2i组降低48.1%,P=0.02),且耐受性良好。
要点
- runcaciguat可显著降低CKD患者白蛋白尿,且不依赖SGLT2i使用。
- 在非糖尿病CKD中UACR较基线下降但未达统计学显著(P=0.10)。
- 严重治疗中出现的不良事件发生率与安慰剂相似(7% vs 8%)。
核心结论
- runcaciguat可改善CKD患者白蛋白尿,无论是否联用SGLT2i,且耐受性良好。
- sGC激活可能成为CKD患者的新型肾脏保护治疗。
研究设计与样本
- 2a期随机、安慰剂对照临床试验(CONCORD),243例随机,229例纳入全分析集,170例纳入符合方案集。
- CKD患者合并动脉粥样硬化性心血管疾病或心力衰竭,以及2型糖尿病和/或高血压。
- 所有患者均接受稳定最大耐受剂量RAS抑制剂,伴或不伴SGLT2i。
- 按3:1随机接受runcaciguat每日一次(30-120mg,耐受则每周滴定)或安慰剂,治疗8周。
- 主要疗效终点为UACR(随机化后第22、29、57天平均值 vs 基线)。
主要发现
- 符合方案集中,不联用SGLT2i的CKD患者UACR较安慰剂降低45.2%(P<0.001)。
- 符合方案集中,联用SGLT2i的CKD患者UACR较安慰剂降低48.1%(P=0.02)。
- 全分析集中,不联用和联用SGLT2i的相对降低分别为46.9%(P<0.001)和44.8%(P=0.01)。
- 联用与不联用SGLT2i患者之间无显著差异。
- 非糖尿病CKD中UACR较基线降低但未达统计学显著(P=0.10)。
临床怎么用
- runcaciguat可能为CKD患者提供不依赖SGLT2i的白蛋白尿降低新选择。
- 需后续研究确认其对硬终点(如eGFR下降、肾衰竭)的影响。
局限性
- 2a期探索性试验,样本量有限(符合方案集170例)。
- 治疗和随访时间短(8周),仅评估白蛋白尿替代终点。
- 非糖尿病CKD亚组未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND HYPOTHESIS: In chronic kidney disease (CKD) the nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway is impaired. Runcaciguat, an sGC activator, activates heme-free sGC, restoring cGMP production. This phase 2a trial studied the efficacy, safety, and tolerability of runcaciguat in CKD patients with or without sodium-glucose co-transporter-2 inhibitor (SGLT2i). METHODS: Patients with CKD and established atherosclerotic cardiovascular disease or heart failure, plus type 2 diabetes (T2D) and/or hypertension, were enrolled. All were receiving stable maximum tolerated renin-angiotensin system inhibitors with or without SGLT2i. They were randomized 3:1 to runcaciguat once daily, titrated weekly (30-120 mg if tolerated), or placebo for 8 weeks. The primary efficacy endpoint was urine albumin-to-creatinine ratio (UACR) (average of post-randomization Days 22, 29, and 57 vs baseline). CONCORD was separately powered for CKD and T2D with stable SGLT2i comedication, CKD and T2D without SGLT2i, and non-diabetic CKD. RESULTS: Of 243 patients randomized, 229 were included in the full analysis set (FAS) and 170 in the per-protocol set (PPS). In the PPS, UACR decreased by -45.2% versus placebo with runcaciguat in patients with CKD without SGLT2i (P < 0.001) and by -48.1% versus placebo in patients with CKD taking SGLT2i (P = 0.02) In the FAS, the relative reductions were -46.9% (P < 0.001) and -44.8% (P = 0.01), respectively. No significant difference was observed between patients with or without SGLT2i. In non-diabetic CKD, UACR was reduced versus baseline with runcaciguat, but the change was not statistically significant (P = 0.10). Serious treatment-emergent adverse events were reported in 7% of patients receiving runcaciguat and 8% receiving placebo. CONCLUSION: Runcaciguat improved albuminuria in patients with CKD, irrespective of concomitant SGLT2i. Runcaciguat was well tolerated. sGC activation may represent a novel kidney-protective treatment in CKD patients (funded by Bayer AG; ClinicalTrials.gov number, NCT04507061).
引用
- Gansevoort RT, Wheeler DC, Debén FM, et al. The soluble guanylate cyclase activator runcaciguat significantly improves albuminuria in patients with chronic kidney disease: a randomized placebo-controlled clinical trial. Nephrol Dial Transplant. 2025. PMID: 39656628. doi:10.1093/ndt/gfae261
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。